MRI After Radiosurgery for Brain Cancer
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Duke University
Disqualifiers: Poor surgical candidate, SCLC, Lymphoma, others
No Placebo Group
Approved in 1 Jurisdiction
Trial Summary
What is the purpose of this trial?The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment MRI after radiosurgery for brain cancer?
Research shows that MRI is very sensitive in tracking changes in brain tumors after radiosurgery, helping doctors distinguish between tumor growth and treatment effects. This means MRI can be a useful tool in monitoring how well the treatment is working.
12345Is MRI safe for humans after radiosurgery for brain cancer?
The studies focus on using MRI to monitor brain changes after radiosurgery, but they do not report any specific safety concerns related to MRI itself. MRI is generally considered safe for humans, as it uses magnetic fields and radio waves, not radiation.
12367How does MRI after radiosurgery for brain cancer differ from other treatments?
This treatment is unique because it uses MRI after stereotactic radiosurgery (a precise form of radiation therapy) to monitor brain cancer, helping to distinguish between tumor regrowth and radiation-induced changes. This approach enhances diagnostic accuracy and aids in decision-making for further treatment.
128910Eligibility Criteria
This trial is for adults over 18 with brain metastasis from solid tumors, excluding small cell lung cancer and lymphoma, who've had stereotactic radiosurgery (SRS). They must be candidates for brain surgery, able to undergo MRI with contrast, and have signed an informed consent.Inclusion Criteria
My cancer has grown at the site previously treated with radiation.
Patients must sign study-specific informed consent prior to study entry
I have been diagnosed with a metastatic cancer that is not small cell lung cancer or lymphoma.
+4 more
Exclusion Criteria
I cannot have an MRI with contrast due to a medical condition or allergy.
My doctors have decided surgery is too risky for me.
My cancer is either small cell lung cancer or lymphoma.
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Radiation
Participants undergo stereotactic radiosurgery (SRS) for brain metastases
Not specified
MRI Evaluation
Participants receive additional MRI sequences to distinguish radiation damage from tumor recurrence
Baseline
Follow-up
Participants are monitored for safety and effectiveness after MRI evaluation
4 weeks
Participant Groups
The study is testing if adding another sequence to the MRI scan can better differentiate between tumor regrowth and radiation damage in patients who've undergone SRS for brain metastases.
1Treatment groups
Experimental Treatment
Group I: MRIExperimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Duke University Health SystemDurham, NC
Loading ...
Who Is Running the Clinical Trial?
Duke UniversityLead Sponsor
References
Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. [2019]With the increasing number of patients successfully treated with stereotactic radiosurgery for brain metastases, decision making after therapy based on follow-up imaging findings becomes more and more important. Magnetic resonance imaging (MRI) is the most sensitive means for follow-up studies. The objective of this study was to investigate the treatment outcome of our radiosurgery program and to describe the response of brain metastases to contrast-enhanced MRI after linear accelerator (linac) stereotactic radiosurgery and identify factors to distinguish among local control and local failure.
Characterisation of Lesions after Stereotactic Radiosurgery for Brain Metastases: Impact of Delayed Contrast Magnetic Resonance Imaging. [2018]To investigate if brain metastases and radiation injuries after stereotactic radiosurgery (SRS) have different signal intensity (SI) time courses up to 55 min after contrast agent application and if delayed contrast magnetic resonance imaging (MRI) contributes to improve diagnostic accuracy.
T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. [2010]We define magnetic resonance imaging (MRI) and clinical criteria that differentiate radiation effect (RE) from tumor progression after stereotactic radiosurgery (SRS).
Serial MR imaging of intracranial metastases after radiosurgery. [2019]To evaluate the spatiotemporal evolution of radiosurgical induced changes both in metastases and in normal brain tissue adjacent to the lesions by serial magnetic resonance (MR) imaging.
Water Exchange Rate Constant as a Biomarker of Treatment Efficacy in Patients With Brain Metastases Undergoing Stereotactic Radiosurgery. [2018]This study was designed to evaluate whether changes in metastatic brain tumors after stereotactic radiosurgery (SRS) can be seen with quantitative MRI early after treatment.
Although Non-diagnostic Between Necrosis and Recurrence, FDG PET/CT Assists Management of Brain Tumours After Radiosurgery. [2017]To re-evaluate the role of (18)F-fluoro-deoxy-D-glucose (FDG) positron emission tomography/ computer assisted tomography (PET/CT) co-registered with magnetic resonance imaging (MRI) in differentiating adverse radiation effect (ARE) from tumour recurrence after Gamma Knife radiosurgery of brain tumours.
Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI. [2018]We sought to determine whether radiation-induced injuries could be distinguished from malignancy after stereotactic radiosurgery (SRS) by analyzing time-dependent changes in lesion morphology on sequential MRI for up to 55min.
Effects of effective stereotactic radiosurgery for brain metastases on the adjacent brain parenchyma. [2021]To evaluate whether functional and metabolic MRI can detect radiation-induced alterations in the adjacent areas after effective stereotactic radiosurgery (SRS) for brain metastases. If confirmed, these techniques may be suited for monitoring the timely stratification of patients for neuroprotective treatments after irradiation.
Radiosurgery and brain tolerance: an analysis of neurodiagnostic imaging changes after gamma knife radiosurgery for arteriovenous malformations. [2019]In order to analyze complications and the factors responsible for the development of serial imaging changes after stereotactic radiosurgery for intracranial arteriovenous malformations, we reviewed serial post-treatment magnetic resonance imaging scans in 72 patients. Median follow-up was 23 months (range 12 to 35 months). Twenty patients developed post-radiosurgical imaging changes consisting of new regions of increased T2 signal on magnetic resonance imaging in brain surrounding the arteriovenous malformation (two year actuarial incidence of 31%). Imaging changes were associated with headache or new neurological deficits in nine of these 20 (45%) and remained asymptomatic in 11 (55%). Symptoms developed in three of 13 patients with imaging changes in the cerebral cortex or cerebellum, in contrast to six of seven patients who had symptoms with imaging changes in the brainstem (p = .028). The onset of imaging changes varied from five to 18 months after radiosurgery (median, 12 months). Serial follow-up scans four to 25 months after the onset of imaging changes were available for review in 16 patients. Post-radiosurgical imaging changes completely resolved within 4 to 19 months in ten patients and have not yet completely resolved after 6 to 25 months in six patients. The projected actuarial rate for resolution of imaging changes was 88%, 19 months after onset; the median time for resolution was 14 months. Univariate analysis revealed that the development of imaging changes was significantly associated with treatment volume (p = .025), the risk predicted from the integrated logistic formula (p = .042), and the number of isocenters treated (p = .042). In multivariate analysis, volume was the only factor significantly associated with the development of imaging changes.
Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. [2015]Stereotactic radiosurgery is a commonly used treatment method in the management of metastatic brain tumors. When lesions enlarge after radiosurgery, it may represent tumor regrowth, radiation necrosis, or both. The purpose of this study was to determine whether standard magnetic resonance imaging (MRI) sequences could reliably distinguish between these pathological possibilities.